New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading ...

The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting ... Experimental Blood Test for Pancreatic Cancer Undergoing Clinical Development ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

Gastroenterologist Dr. Rohan Mandaliya of The Center for Comprehensive Pancreatic Care at Mercy goes over the risk factors of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.